Sarepta tumbles as patient dies following gene therapy treatment

Shares of gene therapy developer Sarepta Therapeutics SRPT.O slump 24.4% to $77.32 in premarket trading

SRPT says a young man with Duchenne muscular dystrophy (DMD) died following treatment with its gene therapy, Elevidys

Says the patient suffered from acute liver failure, a known side effect of Elevidys

Patient had a recent cytomegalovirus infection, which can infect and damage the liver, and was identified by the treating physician as a possible contributing factor - SRPT

DMD is a severe, inherited genetic disorder that causes progressive muscle weakness and degeneration

Up to last close, stock down 18.2% in the last 12 months